Transgender Youth on Hormone Therapy Risk Substantial Bone Loss
It appears that bone health deserves attention when adolescents are placed on gender-affirming hormone therapy.
Source: medscape.com
Stay updated with breaking news from Gnrh Agonists. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It appears that bone health deserves attention when adolescents are placed on gender-affirming hormone therapy.
In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.